WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

CNS Spectrums

Volumn 8, Issue 8 SUPPL. 1, 2003, Pages 53-61

  Allgulander, Christer ^a   Bandelow, Borwin ^b   Hollander, Eric ^b   Montgomery, Stuart A ^b   Nutt, David J ^b   Okasha, Ahmed ^b   Pollack, Mark H ^b   Stein, Dan J ^b   Swinson, Richard P ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CENTRAL DEPRESSANT AGENT; CLORAZEPATE; DELORAZEPAM; DIAZEPAM; IMIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL DISEASE; ANOREXIA; APPETITE DISORDER; BEHAVIOR THERAPY; CHRONICITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFERENCE PAPER; CONSTIPATION; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG ALCOHOL INTERACTION; DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; FATIGUE; GENERALIZED ANXIETY DISORDER; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERHIDROSIS; INSOMNIA; INTERNATIONAL COOPERATION; LONG TERM CARE; MEMORY DISORDER; NAUSEA; NEUROPATHOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RELAXATION TRAINING; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME; WORLD COUNCIL OF ANXIETY; XEROSTOMIA; ANXIETY DISORDER; METHODOLOGY; MULTIMODALITY CANCER THERAPY; REVIEW;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; BENZODIAZEPINES; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 1542319760     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900006945     Document Type: Conference Paper

References (63)

1. Allgulander C. Generalized anxiety disorder. Clinical characteristics and treatment. South African Rev Psychiatry. 2001;1:6-12.
2. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355-364.
3. Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol. 1990;10:101S-110S.
4. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
5. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24:19-39.
6. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. [revised]. Washington, DC: American Psychiatric Association; 1987.
7. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
8. International Classification of Diseases. 10th revision. Geneva, Switzerland: World Health Organization; 1992.
9. Lader MH. The nature and duration of treatment for GAD. Acta Psychiatr Scand. 1998;393(suppl):109-117.
10. Blazer DG, Hughes D, George LK. Generalized anxiety disorder. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991:180-203.
11. Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety. 2001;13:78-88.
12. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol. 2000;15:319-328.
13. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;151:8-19.
14. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990;12:355-362.
15. Souêtre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res. 1994;38(suppl 1): 151-160.
16. Lecrubier Y, Weiller E. GAD: current treatment and costs. Eur Neuropsychopharmacol. 2000;10(suppl 3):170-171.
17. Schweizer E. Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Psychiatr Clin North Am. 1995;18:843-857.
18. Papp LA, Gorman JM. Generalized anxiety disorder. In: Comprehensive Textbook of Psychiatry. 6th ed. Baltimore, Md: Williams and Wilkins; 1995:1236-1249.
19. Environmental factors in the etiology of anxiety. Available at: http://www.acnp.org/g4/GN401000127/Default.htm. Accessed: May 2003.
20. Tiihonen J, Kuikka J, Rasanen P, et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry. 1997;2:463-471.
21. Wu JC, Buchsbaum MS, Hershey TG, Hazlett E, Sicotte N, Johnson JC. PET in generalized anxiety disorder. Biol Psychiatry. 1991;29:1181-1199.
22. Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry. 1999;60(suppl 22):12-17.
23. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 11):22-27.
24. Hamilton M. The assessment of anxiety by rating. Br J Med Psychol. 1959;32:50-55.
25. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US National Institute of Health, Psychopharmacology Research Branch; 1976:217-222.
26. Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety. 1999;9:107-116.
27. Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders. J Affect Disord. 1995;35:153-162.
28. Brawman-Mintzer O. Pharmacologic treatment of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24:119-137.
29. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390-396.
30. Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int Clin Psychopharmacol. 2000;15:99-105.
31. Gorman JM, Papp LA. Chronic anxiety: deciding the length of treatment. J Clin Psychiatry. 1990;51(suppl):11-15.
32. Rickets K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988;45:444-450.
33. Lydiard RB. An overview of generalized anxiety disorder: disease state-appropriate therapy. Clin Ther. 2000;22(suppl A):A3-19.
34. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol. 1996;64:660-668.
35. Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol. 1999;19:86-93.
36. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry. 1996;57:287-291.
37. DeMartinis N, Rynn M, Rickels K, Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2000;61:91-94.
38. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884-895.
39. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988;49:293-301.
40. Hackett D. Venlafaxine XR in the treatment of anxiety. Acta Psychiatr Scand. 2000;102(suppl 46):30-35.
41. Kelsey JE. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Depress Anxiety. 2000;12(suppl 1):81-84.
42. Davidson JR, Dupont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528-535.
43. Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry. 1999;60(suppl 22):23-28.
44. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968-974.
45. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95:444-450.
46. Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 11):46-50.
47. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:350-357.
48. Bellew KM, McCafferty JP, Iyengar M, Zaninelli RM. Paroxetine treatment of GAD: a double-blind placebo-controlled trial. Poster presented at: Annual Meeting of the American Psychiatric Association; May 13-18, 2000; Chicago, Ill.
49. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283:3082-3088.
50. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
51. Stocchi F, Nordera G, Jokinen R, Lepola U. Efficacy and tolerability of paroxetine for the long-term treatment of generalised anxiety disorder (GAD). Poster presented at: Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La.
52. Hackett D, Desmet A, Salinas EO. Dose-response efficacy of venlafaxine XR in GAD. Poster presented at: 11th World Congress of Psychiatry; August 6-11, 1999; Hamburg, Germany.
53. Durham RC, Allan T. Psychological treatment of generalized anxiety disorder. A review of the clinical significance of results in outcome studies since 1980. Br J Psychiatry. 1993;163:19-26.
54. Borkovec TD, Whisman MA. Psychosocial treatment for generalized anxiety disorder. In: Mavissakalian M, Prien R, eds. Long-term Treatment for the Anxiety Disorders. Washington, DC: American Psychiatric Press; 1996:171-199.
55. Fisher PL, Durham RC. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med. 1999;29:1425-1434.
56. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001;62 (suppl 11):37-42.
57. Gould RA, Otto MW, Pollack MH, et al. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behav Ther. 1997;28:285-305.
58. Brown TA, O'Leary TA, Barlow DH. Generalized anxiety disorder. In: Barlow DH, ed. Clinical Handbook of Psychological Disorders. 2nd ed. New York, NY: Guildford; 1993:137-188.
59. Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 1993;61:611-619.
60. Lader MH, Bond AJ. Interaction of pharmacological and psychological treatments of anxiety. Br J Psychiatry. 1998;(suppl 34):42-48.
61. Shapiro AK, Struening EL, Shapiro E. Diazepam: how much better than placebo? J Psychiatr Res. 1983;17:51-73.
62. Power KG, Simpson RJ, Swanson V, Wallace LA. Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract. 1990;40:289-294.
63. Schweizer E, Rickels K. Strategies for treatment of generalized anxiety in the primary care setting. J Clin Psychiatry. 1997;58(suppl 3): 27-31.